The FDA designation that put MDMA and psilocybin on the fast track — what it is, who has it, and what it does not guarantee.
Breakthrough Therapy Designation is an FDA status that speeds up the development and review of a promising drug. It applies when a drug treats a serious condition and early trial data suggests it may be far better than existing options. Congress created it through the FDA Safety and Innovation Act (FDASIA) of 2012.
The goal is simple. When a treatment looks like a real leap forward, the FDA wants to help bring it to patients faster. The designation does not change the safety and effectiveness bar a drug must clear. It changes how quickly and closely the FDA works with the company developing it.
For psychedelics, this designation has been a turning point. It signaled that the FDA took early results for MDMA and psilocybin seriously. It also drew investment and attention to a field that had stalled for decades.
The FDA Safety and Innovation Act was signed into law on July 9, 2012. Section 902 of that law established Breakthrough Therapy Designation. The FDA later issued detailed guidance on how sponsors qualify and what the designation provides.
A drug qualifies for Breakthrough Therapy Designation when preliminary clinical evidence shows substantial improvement over available therapy on a clinically significant endpoint. In plain terms, early human data must hint at a major advantage, not just a small one. The company applies, and the FDA decides.
The designation gives a sponsor several concrete benefits:
The designation is a partnership, not a free pass. The company still has to run rigorous trials and meet the FDA's standards for safety and effectiveness. The benefit is speed and access, not a lower bar. The FDA can also withdraw the designation if later data no longer supports it.
Several psychedelic programs have received Breakthrough Therapy Designation since 2017. Each one targets a serious mental-health condition with limited treatment options. The list below reflects designations confirmed by the sponsors and the FDA.
Breakthrough Therapy is one of four FDA programs designed to speed serious treatments to patients. The four overlap, and a single drug can hold more than one. The table below compares them so you can see what each actually does.
| Pathway | What it requires | Main benefit | Affects the approval bar? |
|---|---|---|---|
| Breakthrough Therapy | Early evidence of substantial improvement over existing therapy | Intensive FDA guidance + senior involvement + rolling review | No — speeds the process only |
| Fast Track | Potential to address an unmet medical need | More frequent FDA meetings; rolling review eligibility | No |
| Accelerated Approval | Effect on a surrogate or intermediate endpoint likely to predict benefit | Approval based on an earlier endpoint, with required follow-up trials | Yes — allows a different endpoint, with conditions |
| Priority Review | A potential major advance in treatment | FDA aims to review the application in 6 months, not 10 | No — shortens review time only |
How to read this: Fast Track and Breakthrough Therapy help during development. Priority Review speeds the final review. Accelerated Approval is the only one that changes what evidence can support approval — and it comes with required confirmatory trials. No psychedelic has reached the approval stage through any of these yet.
Breakthrough Therapy Designation does not mean a drug will be approved. It only speeds development and review. The clearest proof came in August 2024, when the FDA rejected Lykos Therapeutics' MDMA application for PTSD — even though MDMA had held the designation since 2017.
The FDA issued a Complete Response Letter, which is a formal "not yet." An FDA advisory committee had voted in June 2024 that the trials did not show the treatment was effective and that benefits did not outweigh risks. The panel flagged concerns about trial design, functional unblinding, and missing safety data.
This is the single most important point on the page, and it is one that headlines often blur: a Breakthrough drug can still fail at the finish line. The designation reflects early promise, not a final verdict. The FDA can — and did — say no after years of fast-tracked development.
Breakthrough Therapy Designation does not change a substance's legal status. MDMA, psilocybin, and LSD all remain Schedule I under federal law. The designation is about clinical research and FDA review, not about what you can legally possess or use.
It also does not give the public access to these drugs. You cannot buy a Breakthrough-designated psychedelic at a pharmacy or clinic before approval. The main legal route to a designated treatment is enrolling in an approved clinical trial. Use our tool to find a psychedelic clinical trial to see what is recruiting.
For other federal angles, see our guides to the federal Right to Try Act and the NDAA psychedelics provision. For the full legal map, read what psychedelics are legal in the US.
It is an FDA status that speeds up the development and review of a drug for a serious condition when early trial data shows it may be much better than existing treatments. It was created by the FDA Safety and Innovation Act (FDASIA) of 2012. It gives a sponsor intensive FDA guidance, senior involvement, and eligibility for rolling and priority review.
MDMA for PTSD (MAPS, now Lykos, 2017), psilocybin for treatment-resistant depression (COMPASS Pathways, 2018), psilocybin for major depressive disorder (Usona Institute, 2019), and LSD/MM120 for generalized anxiety disorder (MindMed, 2024) have all received it.
No. It only speeds up development and review. It does not guarantee approval. The FDA rejected Lykos Therapeutics' MDMA application for PTSD in August 2024, even though MDMA had held the designation since 2017.
It was created by the FDA Safety and Innovation Act (FDASIA), signed into law on July 9, 2012. Section 902 of that law established the designation.
Breakthrough Therapy includes all Fast Track features but adds more intensive FDA guidance and a senior-leadership commitment. Fast Track needs data showing potential to address an unmet need; Breakthrough Therapy needs stronger early evidence of substantial improvement over existing options.
No. It is a research-and-review status, not a legal change. MDMA, psilocybin, and LSD remain Schedule I under federal law. The designation does not let you legally buy or use these substances outside an approved clinical trial.
Before approval, an approved clinical trial is the main legal route to a Breakthrough-designated psychedelic. Our tools help you find one and check what is legal where you live.
→ Find a psychedelic clinical trial · Check legal status by state
Get FDA Breakthrough Therapy Designation updates
New votes, rules, court rulings, and access changes for FDA Breakthrough Therapy Designation — delivered when they happen.
← Back to all psychedelic laws
Suggest a tool, topic, or improvement that would make this site more useful.